WO2000040254A1 - Pharmaceutical composition for oral administration having therapeutic activity on gastrointestinal disorders - Google Patents
Pharmaceutical composition for oral administration having therapeutic activity on gastrointestinal disorders Download PDFInfo
- Publication number
- WO2000040254A1 WO2000040254A1 PCT/KR1999/000209 KR9900209W WO0040254A1 WO 2000040254 A1 WO2000040254 A1 WO 2000040254A1 KR 9900209 W KR9900209 W KR 9900209W WO 0040254 A1 WO0040254 A1 WO 0040254A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aluminum
- weight
- hydroxide
- magnesium hydroxide
- aceglutamide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Definitions
- the present invention relates to a pharmaceutical composition for oral administration of aceglutamide aluminum (pentakis(N -acetyl-L-glutam -inato)tetrahydroxytrialuminum, C35Hs Al 3 N ⁇ o0 2 ) useful as an anti-ulcerative agent and/or a mixture of aluminum hydroxide and magnesium hydroxide usefiil as an antacid agent. More specifically, the present invention relates to the pharmaceutical composition for oral administration having therapeutic activity on gastrointestinal disorders which comprises aceglutamide aluminum, the mixture of aluminum hydroxide and magnesium hydroxide, or aceglutamide aluminum and the mixture of aluminum hydroxide and magnesium hydroxide as active ingredient, and carrageenan as taste masking agent.
- aceglutamide aluminum penentakis(N -acetyl-L-glutam -inato)tetrahydroxytrialuminum, C35Hs Al 3 N ⁇ o0 2
- the present invention relates to the pharmaceutical composition for oral administration having therapeutic activity
- Aceglutamide aluminum promotes rapid regeneration of damaged gastric mucosa by displaying stimulating activity on production of mucin and constituents of mucosa (Tanaka, H., Gastric cytoprotection of aceglutamide aluminum in rats, Drug Res., 36, 1485-1489(1986)) and recovery of damaged granulation tissue by displaying stimulating activity on formation of granulation (Tanaka, H., Kojima, T. and Marumo, H., Effect of N-acetyl-L-glutamine aluminum complex(KW-HO) on hexosamine content in gastric mucosa, Pharmacometrics 9, 519-522(1975)).
- aceglutamide aluminum is an anti-ulcerative agent which has various mechanisms.
- Korean patent publication No. 96-11773 disclosed that aceglutamide aluminum is administered in combination with antacid agent comprising aluminum hydroxide and magnesium hydroxide in a weight ratio of 1 to 1, wherein a weight ratio of aceglutamide aluminum to the antacid agent is 1 to 1.1 —2.3, thereby to obtain excellent therapeutic effects on digestive ulcers such as gastric or duodenal ulcer.
- the method (i) is inexpensive and simple but has problems in that when active ingredient is very bitter, due to a sweet taste of sweetener, it feels much bitterer than sweetener-free agent on the contrary. Also, in the case of aceglutamide aluminum, although attempts were made to mask its astringent taste by combining it with saccharides such as sucrose, sorbitol, aspartame, etc., its astringent taste became reversely stronger and hence, it became more difficult to take. The method (ii) can effectively mask tastes which cause rejection by patients but the unit cost of manufacturing is elevated since it requires additional manufacturing steps and equipments, and yield is inevitably lowered by involving a coating step.
- Carrageenan is a high molecular weight polymer extracted from plant, seaweed or animal collagen and is a hydrocolloid belonging to polysaccharide family. Structure of carrageenan consists of alternating copolymers of -(l ⁇ 3)-D-galactose and (l ⁇ 4)-3,6-anhydro-D- or L-galactose. Several members of the family are known; they differ in the amount of sulfate ester and/or other substituent groups they carry, for example, t ' ⁇ ta-carrageenan, kappa-carrageenan, etc.
- carrageenan has been used as gelling agents, emulsifying agents, stabilizing agents and viscosity builders in foods and non-foods, but especially milk or water systems.
- carrageenan has never been used in combination with aceglutamide aluminum, aluminum hydroxide or magnesium hydroxide for any use and furthermore, has never been used for masking various tastes including a bitter taste or an astringent taste in any case.
- the present inventors repeated the extensive studies to develop a novel method by which without involving any additional manufacturing step, a bitter and an astringent taste of aceglutamide aluminum and/or a mixture of aluminum hydroxide and magnesium hydroxide can be effectively masked without any adverse effects on pharmacological activity thereof and particularly, in the case of being manufactured into suspension or solution, precipitates are not formed during a period of preservation after being manufactured to obtain a physically stable dosage form.
- the purpose of the present invention is to provide a pharmaceutical composition for oral administration of aceglutamide aluminum and/or a mixture of aluminum hydroxide and magnesium hydroxide, which can effectively mask a bitter and an astringent taste thereof without involving any additional manufacturing step and cost, thereby to improve compliance of patients, to facilitate long-term administration, and furthermore, to obtain a physically stable suspension or solution thereof.
- the present invention provides a pharmaceutical composition for oral administration having therapeutic activity on gastrointestinal disorders characterized by comprising at least one selected from the group consisting of aceglutamide aluminum and a mixture of aluminum hydroxide and magnesium hydroxide as active ingredient and carrageenan as taste masking agent.
- the composition may comprise aceglutamide aluminum alone as active ingredient.
- the composition may comprise aceglutamide aluminum and the mixture of aluminum hydroxide and magnesium hydroxide as active ingredient.
- a weight ratio of aluminum hydroxide to magnesium hydroxide is preferably 1 to 1 and a weight ratio of aceglutamide aluminum to the mixture of aluminum hydroxide and magnesium hydroxide is preferably 1 to 1J — 2.3.
- the above-described compositions comprise 1 —30 parts by weight of aceglutamide aluminum and 0.01 — 10 parts by weight of carrageenan per 100 parts by weight of the composition.
- the composition according to the present invention may comprise the mixture of aluminum hydroxide and magnesium hydroxide as active ingredient.
- the present composition preferably comprises aluminum hydroxide and magnesium hydroxide in a weight ratio of 1 to 1. And it preferably comprises 20 — 50 parts by weight of the mixture of aluminum hydroxide and magnesium hydroxide and 0.01 — 10 parts by weight of carrageenan per 100 parts by weight of the composition.
- the pharmaceutical composition according to the present invention may be pharmaceutically manufactured into a dosage form selected from the group consisting of powder, granule, dry syrup, suspension, solution and chewable tablet in combination with pharmaceutically acceptable excipients. It is preferable that the composition is pharmaceutically manufactured into suspension or solution.
- the composition preferably comprises 0.01 — 0J parts by weight of carrageenan per 100 parts by weight of the composition. More preferably, the composition further comprises sweeteners or aromatics.
- the bitter and the astringent taste can be effectively masked without involving any additional manufacturing step or cost.
- the present inventors performed many experiments to find out which polysaccharides can effectively mask the bitter and the astringent taste among many kinds of polysaccharides and as a result, found out that carrageenan only can effectively mask the tastes. Also, they discovered that carrageenan can most effectively mask the bitter and the astringent taste of aceglutamide aluminum, aluminum hydroxide and magnesium hydroxide, among various agents.
- aceglutamide aluminum in a pharmaceutical composition for oral administration comprising aceglutamide aluminum, although an amount of aceglutamide aluminum is variable according to its dosage form, it is preferably 1 — 30 parts by weight, more preferably, 2 — 20 parts by weight, per 100 parts by weight of the composition, since within the above range of amount, aceglutamide aluminum is expected to sufficiently display its pharmacological effects.
- a pharmaceutical composition for oral administration of a mixture of aluminum hydroxide and magnesium hydroxide preferably comprises 20 — 50 parts by weight of the mixture of aluminum hydroxide and magnesium hydroxide per 100 parts by weight of the composition.
- the above-described compositions comprise 0.01 — 10 parts by weight of carrageenan, since in the case of more than 10 parts by weight, their viscosity becomes too high and thus, they involve some problems in being pharmaceutically manufactured into dosage forms by conventional methods, and in the case of less than 0.01 parts by weight, due to too small amount of carrageenan, tastes cannot be effectively masked.
- the present composition comprises aceglutamide aluminum in combination with a mixture of aluminum hydroxide and magnesium hydroxide, according to Korean patent publication No. 96-11773, the content of which is incorporated hereinto by reference, it is preferable that a weight ratio of aluminum hydroxide to magnesium hydroxide is 1 to 1 and a weight ratio of aceglutamide aluminum to the mixture of aluminum hydroxide and magnesium hydroxide is 1 to 1J — 2.3, since excellent therapeutic effects on digestive ulcers can be obtained in the above-described ratios.
- the pharmaceutical composition according to the present invention may be pharmaceutically manufactured into various dosage forms, for example, powder, granule, dry syrup, suspension, solution or chewable tablet, in combination with pharmaceutically acceptable excipients, by conventional methods.
- Carrageenan has characteristic flow, so called “pseudoplastic flow", characterized by without any external stimulus, high viscosity being maintained but with any external stimulus, viscosity being steeply decreased. Therefore, carrageenan is the optimal excipient for suspension wherein suspension stability is important during a period of preservation, or solution. Therefore, provided that the composition according to the present invention is manufactured into suspension or solution, it can be comfortably taken by patients and is stable without precipitates during a period of preservation after being manufactured.
- the present composition preferably comprises 0.01 — 0J parts by weight of carrageenan per 100 parts by weight of the composition. That is, if more than 0J parts by weight of carrageenan is present, the composition will have too high viscosity and thus, lose fluidity, a principal characteristic of liquid dosage forms. If less than 0.01 parts by weight of carrageenan is present, an amount of carrageenan is too small and thus, tastes cannot be effectively masked.
- liquid dosage forms such as suspension or solution are characterized in that patients feel bitterer or more astringent than solid dosage forms
- a bitter and an astringent taste are preliminary masked and subsequently, to be rendered to have tastes suitable for taking
- it preferably further comprises conventional sweeteners.
- sweeteners sucrose, sorbitol, stevioside or mixtures thereof may be added thereto.
- a weight ratio of aceglutamide aluminum to sweeteners is 1 to 1 — 10.
- it may also further comprise conventional aromatics.
- Powder of aceglutamide aluminum was manufactured according to a conventional method for manufacturing powder, using the composition as shown in the following table 1.
- Granules of aceglutamide aluminum were manufactured according to a conventional method for manufacturing granules, using the composition as shown in the following table 2.
- Solution of aceglutamide aluminum was manufactured according to a conventional method for manufacturing solution, using the composition as shown in the following table 3.
- Chewable tablets of aceglutamide aluminum, a weight of which was 2.5g/tablet, were manufactured according to a conventional method for manufacturing chewable tablets, using the composition as shown in the following table 5. Table. 5
- Solution of aceglutamide aluminum was manufactured in the substantially same method as in example 3 except that carrageenan was not used.
- organoleptic tests were carried out on solutions of aceglutamide aluminum obtained from example 3 and comparative example 1, respectively. Organoleptic tests were proceeded with by two-point contrast method which can be used in judgement of simple differences, indication of differences and selection of quality. Panel participating in the tests consisted of 27 members regardless of sex who had no prejudice on dosage forms according to the present invention. In the case of the above described method, a percentage of a correct answer was 50% and results were tested according to ⁇ test and significance test table of two-point contrast method. In addition, after the members tasted, grade No. 1 was given to a preferable sample and grade No. 2 given to an unpreferable sample. The results were shown in the following table 6.
- the pharmaceutical composition according to the present invention can effectively mask a bitter and an astringent taste of aceglutamide aluminum and/or a mixture of aluminum hydroxide and magnesium hydroxide without involving any additional manufacturing step or cost thereby to improve compliance of patients, to facilitate long-term administration and furthermore, to obtain a physically stable suspension or solution.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2001-7000075A KR100370391B1 (en) | 1998-12-31 | 1999-04-29 | Pharmaceutical composition for oral administration having therapeutic activity on gastrointestinal disorders |
AU34442/99A AU3444299A (en) | 1998-12-31 | 1999-04-29 | Pharmaceutical composition for oral administration having therapeutic activity on gastrointestinal disorders |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019980063716A KR20000046974A (en) | 1998-12-31 | 1998-12-31 | Composition for oral administration comprising aceglutamide aluminum and carageenan |
KR1998/63716 | 1998-12-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000040254A1 true WO2000040254A1 (en) | 2000-07-13 |
Family
ID=19570278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR1999/000209 WO2000040254A1 (en) | 1998-12-31 | 1999-04-29 | Pharmaceutical composition for oral administration having therapeutic activity on gastrointestinal disorders |
Country Status (4)
Country | Link |
---|---|
KR (2) | KR20000046974A (en) |
CN (1) | CN1175820C (en) |
AU (1) | AU3444299A (en) |
WO (1) | WO2000040254A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010130393A2 (en) * | 2009-05-12 | 2010-11-18 | Ratiopharm Gmbh | Orodispersible tablet containing a vardenafil salt |
JP2020516660A (en) * | 2017-04-13 | 2020-06-11 | デーウン ファーマシューティカル カンパニー リミテッド | Suspension containing aluminum hydroxide and magnesium hydroxide and method for producing the same |
RU2795006C2 (en) * | 2017-04-13 | 2023-04-27 | Тэвун Фармасьютикал Ко., Лтд. | Suspension containing aluminum hydroxide and magnesium hydroxide and method for its production |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2010006829A (en) * | 2007-12-20 | 2010-09-30 | Nutricia Nv | Liquid nucleotides/nucleosides-containing product. |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0248740A2 (en) * | 1986-06-06 | 1987-12-09 | Terumo Kabushiki Kaisha | A composition of aluminium hydroxide gel |
US5013557A (en) * | 1989-10-03 | 1991-05-07 | Warner-Lambert Company | Taste masking compositions comprising spray dried microcapsules containing sucralfate and methods for preparing same |
JPH10101580A (en) * | 1996-09-27 | 1998-04-21 | Eisai Co Ltd | Composition hiding unpleasant taste of medicine |
WO1998043675A1 (en) * | 1997-03-28 | 1998-10-08 | Eisai Co., Ltd. | Oral pharmaceutical preparations decreased in bitterness by masking |
-
1998
- 1998-12-31 KR KR1019980063716A patent/KR20000046974A/en not_active Application Discontinuation
-
1999
- 1999-04-29 WO PCT/KR1999/000209 patent/WO2000040254A1/en active IP Right Grant
- 1999-04-29 CN CNB998152579A patent/CN1175820C/en not_active Expired - Lifetime
- 1999-04-29 KR KR10-2001-7000075A patent/KR100370391B1/en not_active IP Right Cessation
- 1999-04-29 AU AU34442/99A patent/AU3444299A/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0248740A2 (en) * | 1986-06-06 | 1987-12-09 | Terumo Kabushiki Kaisha | A composition of aluminium hydroxide gel |
US5013557A (en) * | 1989-10-03 | 1991-05-07 | Warner-Lambert Company | Taste masking compositions comprising spray dried microcapsules containing sucralfate and methods for preparing same |
JPH10101580A (en) * | 1996-09-27 | 1998-04-21 | Eisai Co Ltd | Composition hiding unpleasant taste of medicine |
WO1998043675A1 (en) * | 1997-03-28 | 1998-10-08 | Eisai Co., Ltd. | Oral pharmaceutical preparations decreased in bitterness by masking |
Non-Patent Citations (3)
Title |
---|
CHEMICAL ABSTRACTS, vol. 122, no. 15-22, May 1995, Columbus, Ohio, US; abstract no. 256024C, JANG ET. AL.: "Effect of Antacids, Aceglutamide Alumnium or their Combination on Acute and Chronid Ulcer Models in Rats." page 102; column 1; * |
PATENT ABSTRACTS OF JAPAN * |
YAKHAK HOECHI, vol. 38, no. 5, 1994, KOREAN * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010130393A2 (en) * | 2009-05-12 | 2010-11-18 | Ratiopharm Gmbh | Orodispersible tablet containing a vardenafil salt |
WO2010130393A3 (en) * | 2009-05-12 | 2011-10-20 | Ratiopharm Gmbh | Orodispersible tablet containing a vardenafil salt |
JP2020516660A (en) * | 2017-04-13 | 2020-06-11 | デーウン ファーマシューティカル カンパニー リミテッド | Suspension containing aluminum hydroxide and magnesium hydroxide and method for producing the same |
EP3610857A4 (en) * | 2017-04-13 | 2020-09-16 | Daewoong Pharmaceutical Co., Ltd. | Suspension comprising aluminum hydroxide and magnesium hydroxide and preparation method therefor |
US11135165B2 (en) | 2017-04-13 | 2021-10-05 | Daewoong Pharmaceutical Co., Ltd. | Suspension comprising aluminum hydroxide and magnesium hydroxide and preparation method therefor |
JP7090641B2 (en) | 2017-04-13 | 2022-06-24 | デーウン ファーマシューティカル カンパニー リミテッド | Suspension containing aluminum hydroxide and magnesium hydroxide and its manufacturing method |
RU2795006C2 (en) * | 2017-04-13 | 2023-04-27 | Тэвун Фармасьютикал Ко., Лтд. | Suspension containing aluminum hydroxide and magnesium hydroxide and method for its production |
AU2018251519B2 (en) * | 2017-04-13 | 2023-06-15 | Daewoong Pharmaceutical Co., Ltd. | Suspension comprising aluminum hydroxide and magnesium hydroxide and preparation method therefor |
Also Published As
Publication number | Publication date |
---|---|
KR20010086297A (en) | 2001-09-10 |
AU3444299A (en) | 2000-07-24 |
KR100370391B1 (en) | 2003-01-30 |
CN1175820C (en) | 2004-11-17 |
CN1332630A (en) | 2002-01-23 |
KR20000046974A (en) | 2000-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69918105T2 (en) | ORAL PREPARATION CONTAINING A BIGUANIDE AND AN ORGANIC ACID | |
EP1827386B1 (en) | Oral compositions for absorption of phosphorus compounds | |
DE3931215C2 (en) | Pharmaceutical preparations based on ranitidine | |
US20070298100A1 (en) | Compressed Pharmaceutical Compositions Comprising Peg and Electrolytes | |
RU2241460C2 (en) | Cefuroxime axetyl-containing pharmaceutical composition with masked bitter taste | |
US7727552B1 (en) | Oral pharmaceutical preparations decreased in bitterness by masking | |
JPH0363219A (en) | Aqueous drug suspension for substantially water- insoluble drug activator | |
JPH0248525B2 (en) | ||
EP0858801A1 (en) | Chewable tablet | |
JP2711759B2 (en) | Antidiarrheal composition | |
JP2818220B2 (en) | Composition containing water-containing organic solvent extract for food, composition containing water-containing organic solvent extract for medicine, and methods for producing them | |
US20130189377A1 (en) | Compositions | |
EP0379753A1 (en) | N-acetyl glucosamine preparations for buccal use | |
US4837255A (en) | Palatable hypocholesterolaemic gel formulation containing a pharmaceutically acceptable non-digestible anion exchange resin | |
WO2011072839A1 (en) | Orodispersible tablet, containing dapoxetine | |
WO2000040254A1 (en) | Pharmaceutical composition for oral administration having therapeutic activity on gastrointestinal disorders | |
DE2726392A1 (en) | MEANS FOR CONTROL OF VENOUS THROMBOSIS | |
EP2046387A1 (en) | Masking the taste of compositions containing salt | |
EP0424706B1 (en) | Chewable or suckable pharmaceutical form, process for its preparation and its use | |
JP3596742B2 (en) | Cation exchange resin formulation | |
KR100675081B1 (en) | Acetylcysteine oral dosage forms | |
CA2376258A1 (en) | Oral preparations of etidronate disodium | |
KR100907201B1 (en) | Liquid medicine for internal use | |
CN113784711A (en) | Orally disintegrating tablet comprising glycopyrronium bromide and method for increasing bioavailability | |
WO1996008238A1 (en) | Use of paracellular absorption enhancers such as glucose for enhaincing the absorption of histamine h2-antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99815257.9 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1020017000075 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017000075 Country of ref document: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
WWG | Wipo information: grant in national office |
Ref document number: 1020017000075 Country of ref document: KR |